Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.94 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.94 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.94 |
| ▸ | TSPO | P30536 | 1/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.94 |
| ▸ | HRH1 | P35367 | 1/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.94 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.94 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.94 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiotropium SCHEMBL27894301 | 1.00 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL6337148 | 0.99 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL29206611 | 0.99 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL27726355 | 0.99 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL19471214 | 0.99 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL28716206 | 0.99 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL2231775 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL433959 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL28707361 | 0.99 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL2231780 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109963557-A | The tiotropium of atomization | 格兰马克专业公司 | 2019-07-02 | — | — | CN | claimed |
| EP-3556435-B1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3556435-A1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2019-10-23 | — | — | EP | disclosed |
| CN-106255689-B | Heteroaryl SYK Inhibitors | 勃林格殷格翰国际有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110183440-A | Heteroaryl SYK inhibitor | 勃林格殷格翰国际有限公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-109789131-A | Pharmaceutical composition | 墨西哥氟石股份公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-105193773-B | The breathing of activating agent delivers | 珍珠治疗公司 | 2018-12-11 | — | — | CN | disclosed |
| CN-104870449-B | Compound (I) | 奇斯药制品公司 | 2018-11-06 | — | — | CN | disclosed |
| CN-108619148-A | A kind of new medical use of Tiotropium Bromide and Formoterol compound sucking preparation | 杭州勃锐思莫生物医药科技有限责任公司 | 2018-10-09 | — | — | CN | disclosed |
| CN-108451936-A | A kind of Tiotropium Bromide sucking preparation prepare treat lung-cancer medicament in apply | 杭州勃锐思莫生物医药科技有限责任公司 | 2018-08-28 | — | — | CN | disclosed |
| CN-107669664-A | Composition and correlation technique and system through breathing delivering activating agent | 珍珠治疗公司 | 2018-02-09 | — | — | CN | disclosed |
| CN-107666903-A | Multiple medicine fragility base composition | 得克萨斯州大学系统董事会 | 2018-02-06 | — | — | CN | disclosed |
| CN-107430117-A | Detection and quantitative IL 13 method and the purposes in diagnosing and treating Th2 relevant diseases | 豪夫迈·罗氏有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107412212-A | Transpulmonary delivery of long-acting muscarinic antagonist and long-acting beta2The composition and correlation technique and system of 3 adrenergic receptor agonists | 珍珠治疗公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107205936-A | Composition comprising at least one dry powder obtained by spray drying for increasing the stability of the formulation | 纪元技术有限责任公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-102596176-B | Compositions for respiratory delivery of active agents and related methods and systems | 珍珠治疗公司 | 2017-09-19 | — | — | CN | disclosed |
| CN-107108577-A | New compound | 奇斯药制品公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-107007557-A | A kind of medicinal flower-shape carrier particles for customizing nano-pore structure and preparation method thereof | 谭淞文 | 2017-08-04 | — | — | CN | disclosed |
| CN-106977575-A | Method for preparing FLUTICASONE PROPIONATE form 1 | 辉瑞股份有限公司 | 2017-07-25 | — | — | CN | disclosed |
| CN-103687483-A | Compositions, methods and systems for respiratory delivery of two or more active agents | PEARL THERAPEUTICS INC | 2014-03-26 | — | — | CN | disclosed |